Please login to the form below

Not currently logged in
Email:
Password:

Novartis' former UK government affairs head launches consultancy

Oxygen Strategy will offer pharma clients a 'fresh approach to strategy'

Oxygen StrategyHenry Burkitt, former head of government affairs and policy at Novartis UK, has launched a new healthcare consultancy specialising in providing strategic policy advice for pharmaceutical clients.

Oxygen Strategy, which is based in London, hopes to change the increasingly discordant relationship between pharma and the NHS by offering companies a “fresh approach to strategy”.

In doing so the firm aims to challenge conventional tactics and create a range of new and disruptive methods in public affairs strategy development, project management, behaviour-change programmes and account transformation.

Drawing on 15 years of pharma and charity advisory experience, Burkitt said: “Traditional lobbying has failed to fix the broken relationship between the pharmaceutical industry and the NHS.

“Adversarial ways of working can harm patients and damage the commercial market for life sciences, which we need to protect in a post-Brexit world.

“My experience of helping pharmaceutical companies cooperate with the NHS, combined with my frustration over conventional lobbying, has inspired me to launch this new business.”

The Oxygen Strategy team will also work to stimulate debate about policy reform in the public affairs and market access spheres, as part of the consultancy's efforts to address counter-productive policies in the healthcare sector.

Burkitt added: “I believe it's an approach that will lead to better commercial outcomes and significant benefits for the health service.”

Article by
Rebecca Clifford

20th December 2016

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics